Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Angelo Ghezzi

Showing results (101-110 of 133) with videos related to

Pageof 14
Sort By:
Neurology|July 29, 2016
History of multiple sclerosis in 2 successive pregnancies: A French and Italian cohortAmandine Benoit, Françoise Durand-Dubief, Maria-Pia Amato, et al.
The New England Journal of Medicine|September 13, 2018
Trial of Fingolimod versus Interferon Beta-1a in Pediatric Multiple SclerosisTanuja Chitnis, Douglas L Arnold, Brenda Banwell, et al.
JAMA Neurology|May 3, 2021
Risk of Persistent Disability in Patients With Pediatric-Onset Multiple SclerosisDamiano Baroncini, Marta Simone, Pietro Iaffaldano, et al.
JAMA Neurology|July 1, 2014
Treatment of relapsing-remitting multiple sclerosis after 24 doses of natalizumab: evidence from an Italian spontaneous, prospective, and observational study (the TY-STOP Study)Marinella Clerico, Irene Schiavetti, Stefania F De Mercanti, et al.
Journal of Neurology, Neurosurgery, and Psychiatry|March 6, 2020
Effect of fingolimod on MRI outcomes in patients with paediatric-onset multiple sclerosis: results from the phase 3 PARADIG<i>MS</i> studyDouglas L Arnold, Brenda Banwell, Amit Bar-Or, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|July 8, 2020
Temporal profile of lymphocyte counts and relationship with infections with fingolimod therapy in paediatric patients with multiple sclerosis: Results from the PARADIG<i>MS</i> studyTanuja Chitnis, Brenda Banwell, Lauren Krupp, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|August 6, 2010
The management of multiple sclerosis in children: a European viewAngelo Ghezzi, Brenda Banwell, Alexey Boyko, et al.
Neurological Sciences : Official Journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology|July 5, 2022
Long-term follow-up (up to 11 years) of an Italian pediatric MS cohort treated with Natalizumab: a multicenter, observational studyDamiano Baroncini, Angelo Ghezzi, Clara Guaschino, et al.
Journal of Neurology, Neurosurgery, and Psychiatry|January 10, 2014
Postpartum relapses increase the risk of disability progression in multiple sclerosis: the role of disease modifying drugsEmilio Portaccio, Angelo Ghezzi, Bahia Hakiki, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|February 13, 2016
The cognitive reserve theory in the setting of pediatric-onset multiple sclerosisLuisa Pastò, Emilio Portaccio, Benedetta Goretti, et al.
Pageof 14

Showing results (101-110 of 133) with videos related to

Sort By:
Pageof 14
Neurology|July 29, 2016
History of multiple sclerosis in 2 successive pregnancies: A French and Italian cohortAmandine Benoit, Françoise Durand-Dubief, Maria-Pia Amato, et al.
The New England Journal of Medicine|September 13, 2018
Trial of Fingolimod versus Interferon Beta-1a in Pediatric Multiple SclerosisTanuja Chitnis, Douglas L Arnold, Brenda Banwell, et al.
JAMA Neurology|May 3, 2021
Risk of Persistent Disability in Patients With Pediatric-Onset Multiple SclerosisDamiano Baroncini, Marta Simone, Pietro Iaffaldano, et al.
JAMA Neurology|July 1, 2014
Treatment of relapsing-remitting multiple sclerosis after 24 doses of natalizumab: evidence from an Italian spontaneous, prospective, and observational study (the TY-STOP Study)Marinella Clerico, Irene Schiavetti, Stefania F De Mercanti, et al.
Journal of Neurology, Neurosurgery, and Psychiatry|March 6, 2020
Effect of fingolimod on MRI outcomes in patients with paediatric-onset multiple sclerosis: results from the phase 3 PARADIG<i>MS</i> studyDouglas L Arnold, Brenda Banwell, Amit Bar-Or, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|July 8, 2020
Temporal profile of lymphocyte counts and relationship with infections with fingolimod therapy in paediatric patients with multiple sclerosis: Results from the PARADIG<i>MS</i> studyTanuja Chitnis, Brenda Banwell, Lauren Krupp, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|August 6, 2010
The management of multiple sclerosis in children: a European viewAngelo Ghezzi, Brenda Banwell, Alexey Boyko, et al.
Neurological Sciences : Official Journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology|July 5, 2022
Long-term follow-up (up to 11 years) of an Italian pediatric MS cohort treated with Natalizumab: a multicenter, observational studyDamiano Baroncini, Angelo Ghezzi, Clara Guaschino, et al.
Journal of Neurology, Neurosurgery, and Psychiatry|January 10, 2014
Postpartum relapses increase the risk of disability progression in multiple sclerosis: the role of disease modifying drugsEmilio Portaccio, Angelo Ghezzi, Bahia Hakiki, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|February 13, 2016
The cognitive reserve theory in the setting of pediatric-onset multiple sclerosisLuisa Pastò, Emilio Portaccio, Benedetta Goretti, et al.
Pageof 14